Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: are we asking the right questions?

Barrett JS, McGuire J, Vezina H, Spitsin S, Douglas SD.

J Clin Psychopharmacol. 2013 Dec;33(6):725-8. doi: 10.1097/JCP.0b013e3182a88654.

PMID:
24100788
2.

[Clinical evaluation of CNS drugs with PET].

Takano A.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2009 Apr;29(2):61-5. Review. Japanese.

PMID:
19562943
3.

Guidelines to PET measurements of the target occupancy in the brain for drug development.

Takano A, Varrone A, Gulyás B, Salvadori P, Gee A, Windhorst A, Vercouillie J, Bormans G, Lammertsma AA, Halldin C.

Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2255-2262. Epub 2016 Aug 11.

4.
5.

Positron emission tomography in CNS drug discovery and drug monitoring.

Piel M, Vernaleken I, Rösch F.

J Med Chem. 2014 Nov 26;57(22):9232-58. doi: 10.1021/jm5001858. Epub 2014 Sep 10. Review.

PMID:
25144329
6.

Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain.

Elsinga PH, Hendrikse NH, Bart J, van Waarde A, Vaalburg W.

Mol Imaging Biol. 2005 Jan-Feb;7(1):37-44. Review.

PMID:
15912274
7.

The role of imaging in proof of concept for CNS drug discovery and development.

Wong DF, Tauscher J, Gründer G.

Neuropsychopharmacology. 2009 Jan;34(1):187-203. doi: 10.1038/npp.2008.166. Epub 2008 Oct 8. Review.

8.

Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates.

Schou M, Varnäs K, Lundquist S, Nakao R, Amini N, Takano A, Finnema SJ, Halldin C, Farde L.

Int J Neuropsychopharmacol. 2015 Mar 26;18(10):pyv036. doi: 10.1093/ijnp/pyv036.

9.

Imaging in Central Nervous System Drug Discovery.

Gunn RN, Rabiner EA.

Semin Nucl Med. 2017 Jan;47(1):89-98. doi: 10.1053/j.semnuclmed.2016.09.001. Epub 2016 Oct 28. Review.

PMID:
27987561
10.

Translational PET imaging research.

Hargreaves RJ, Rabiner EA.

Neurobiol Dis. 2014 Jan;61:32-8. doi: 10.1016/j.nbd.2013.08.017. Epub 2013 Sep 17. Review.

PMID:
24055214
11.

Simulation of PET scan timings for receptor occupancy studies of CNS drugs: a simple fixed-time design performed as well as scattered time point designs.

Lee J, Jeon S, Hong T, Han S, Yim DS.

Eur J Clin Pharmacol. 2015 Nov;71(11):1333-9. doi: 10.1007/s00228-015-1933-9. Epub 2015 Sep 9.

PMID:
26350521
12.

[Molecular imaging in the drug development of psychotropics using positron emission tomography].

Takano H, Takahashi H, Ito H, Suhara T.

Brain Nerve. 2007 Mar;59(3):215-20. Review. Japanese.

PMID:
17370647
13.

Positron Emission Tomography: applications in drug discovery and drug development.

Wang J, Maurer L.

Curr Top Med Chem. 2005;5(11):1053-75. Review.

PMID:
16181131
14.

Using positron emission tomography to facilitate CNS drug development.

Lee CM, Farde L.

Trends Pharmacol Sci. 2006 Jun;27(6):310-6. Epub 2006 May 6. Review.

PMID:
16678917
15.

The role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animals.

Roselt P, Meikle S, Kassiou M.

Eur J Drug Metab Pharmacokinet. 2004 Jan-Mar;29(1):1-6. Review.

PMID:
15151164
16.

Molecular imaging with SPECT as a tool for drug development.

Gomes CM, Abrunhosa AJ, Ramos P, Pauwels EK.

Adv Drug Deliv Rev. 2011 Jun 19;63(7):547-54. doi: 10.1016/j.addr.2010.09.015. Epub 2010 Oct 8. Review.

PMID:
20933557
18.

Positron emission tomography imaging as a key enabling technology in drug development.

McCarthy TJ.

Ernst Schering Res Found Workshop. 2007;(62):329-39. Review.

PMID:
17172162
19.

Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.

Yoshida A, Maruyama S, Fukumoto D, Tsukada H, Ito Y, Yamada S.

Life Sci. 2010 Jul 31;87(5-6):175-80. doi: 10.1016/j.lfs.2010.06.008. Epub 2010 Jun 18.

PMID:
20598326
20.

D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection.

Schmidt ME, de Boer P, Andrews R, Neyens M, Rossenu S, William Falteos D, Mannaert E.

Psychopharmacology (Berl). 2012 Dec;224(4):549-57. doi: 10.1007/s00213-012-2782-1. Epub 2012 Jul 7.

PMID:
22773165

Supplemental Content

Support Center